Please assess the completion status of the following clinical trial:

Trial Title: Randomized, Double-Blind Study Comparing Dexelvucitabine (DFC) to Lamivudine (3TC) in Subjects With Resistance to NRTIs, PIs, and NNRTIs

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* a) Male (at birth) subjects, between 16 years (or the legal age of consent, whichever is older) and 75 years of age, utilizing adequate contraceptive methods.~* b) Female (at birth) subjects between 16 years (or the legal age of consent, whichever is older) and 75 years of age.~* Women of childbearing potential may be enrolled following a negative serum pregnancy test. If participating in activity that could lead to pregnancy, women shall agree to use TWO forms of contraception as listed in # 1-4 below (at least one must be a barrier method) while receiving protocol-specified medication and for 2 months after stopping the medication.~  1. Condom (male or female) with or without a spermicidal agent~ 2. Diaphragm or cervical cap with spermicide~ 3. IUD~ 4. Hormonal-based contraception~* Women who are not of reproductive potential (documented to be surgically sterile or postmenopausal \[defined as amenorrhea \>1 year and follicle stimulating hormone {FSH} \>30 mU/mL\]) are eligible to be enrolled without a serum pregnancy test and will not be required to use contraception.~* Subjects treated with a HAART regimen(s), including a minimum of 3 drugs, for at least 3 months and who have been on a stable HAART regimen for a minimum of 8 weeks prior to the Screening visit. The HAART regimen must also remain stable from the Screening visit until randomization on Day 0 in order for the subject to qualify for enrollment.~* Demonstrate evidence of failure of at least 3 drug classes, defined as #s 1-3 below:~  1. Prior NRTI use and presence of one or more NRTI-resistance-conferring mutations, including mutations at RT amino acids 41L, 65R, 67N, 70R, 74V or 74I, 184V or 184I, 210W, 215Y or 215F, and/or 219Q or 219E.~ 2. Presence of one or more NNRTI-resistance conferring mutations, including mutations at RT amino acids 100I, 101E or 101P, 103N, 106A or 106M, 188L, and/or 190A or 190S or 190E at Screening or documented to be present on a prior genotype OR documented evidence of prior NNRTI use of at least 2 months duration with viral load ≥1000 copies/mL after at least 2 months of treatment.~ 3. Prior ritonavir-boosted PI use AND presence of one or more PI-resistance-conferring mutations, including mutations at protease amino acids 33F, 46I or 46L, 50V, 82A or 82F or 82T or 82S, 84V, and/or 90M.~* Demonstrate a Screening plasma HIV RNA concentration of ³1000 copies/mL (Roche Amplicor HIV-1 Monitor® Test, v1.5 - Quantitative assay) and, in the expert judgment of the investigator, be failing the current regimen.~* Be able and willing to provide written informed consent.~* Be able and willing to comply, in the opinion of the investigator, with the requirements of this study.~Exclusion Criteria:~* Current or recent (\<30 days) opportunistic infection (Category C according to the Centers for Disease Control (CDC) Classification System for HIV-1 Infection, 1993 Revised Version) that is not being controlled by medication in the judgment of the investigator.~* Subjects who are, in the opinion of the investigator, unable to comply with the dosing schedule and protocol evaluations.~* Pregnant women or women who are breastfeeding~* Current alcohol or drug use, which in the expert judgment of the investigator, will interfere with the subject's ability to comply with the protocol requirements.~* Subjects treated with dexelvucitabine (formerly known as Reverset) in a prior investigational drug protocol.~* Subjects with a history of acute or chronic pancreatitis.~* Subjects with acute hepatitis B and/or C infection.~* Subjects with unstable chronic hepatitis.~* Subjects with chronic renal failure requiring dialysis.~* Subjects currently receiving 3TC or FTC as part of a regimen for treatment of stable, chronic HBV infection. Subjects with stable chronic HBV infection who are being treated with entecavir, adefovir, or tenofovir are eligible to enroll.~* Subjects with the following laboratory parameters within 35 days prior to first dose of study medication:~  * Hemoglobin \<9.0 g/dL (males) or \<8.0 g/dL (females)~ * Absolute neutrophil count (ANC) \<750/mm3~ * Platelet count \<75 000/mm3~ * Aspartate aminotransaminase (AST \[SGOT\]) or alanine aminotransaminase (ALT \[SGPT\]) \>5 X upper limit of normal (ULN)~ * Serum lipase \>1.5 X ULN~ * Serum creatinine \> 3.0 x ULN~* Subjects who have received an HIV prophylactic or corrective vaccination within 6 months prior to the first dose of study medication.~* Subjects who have received radiation therapy or cytotoxic chemotherapeutic agents and have not recovered from side effects prior to the first dose of study medication.~* Subjects with RT mutations Q151M or T69SS on Screening genotype.

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Dexelvucitabine (DFC) (Type: EXPERIMENTAL): 200 mg once daily
- lamivudine (3TC) (Type: ACTIVE_COMPARATOR): 300 mg once daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy